S100A8 and myocardial infarction: In rats subjected to coronary ligation, the administration of the S100A8/A9 inhibitor ABR-215757 (5 mg/kg, daily for 5 days) led to a notable decrease in fibrotic areas surrounding the myocardial infarction margins and a reduction in NF-κB p65 protein levels (69).